Eli Lilly stock jumped in pre-market trade after the company reported much higher sales and profit than expected. Their weight loss and diabetes drugs, Mounjaro and Zepbound, drove huge growth. Looking ahead, the company predicts it will earn up to $83 billion in 2026, showing strong confidence.